baxdrostat safety, tolerability, pharmacokinetic and pharmacodynamic study in a Japanese population

Trial Identifier:	CIN-107-126
Sponsor:	AstraZeneca
NCTID::	NCT05966324
Start Date:	July 2022
Primary Completion Date:	September 2022
Study Completion Date:	September 2022
Condition:	Hypertension

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
United States, California	Anaheim, California, United States, 92801

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.